The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2
- PMID: 32971147
- PMCID: PMC7505773
- DOI: 10.1016/j.biochi.2020.09.018
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2
Abstract
An acute respiratory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that surfaced in China in late 2019, continues to spread rapidly across the globe causing serious concerns. The coronavirus disease 2019 (COVID-19) is declared as a public health emergency worldwide by the World Health Organization (WHO). Increasing evidences have demonstrated human-to-human transmission that primarily affects the upper respiratory tract followed by lower respiratory tract damage leading to severe pneumonia. Based on the current status, the elderly population and people with prior co-morbidities are highly susceptible to serious health effects including cytokine up-regulation and acute respiratory distress syndrome (ARDS). Currently, COVID-19 research is still in the preliminary stage necessitating rigorous studies. There is no specific drug or vaccine targeting SARS-CoV-2 currently and only symptomatic treatment is being administered, but several antivirals are under active investigation. In this review, we have summarized the epidemiology, entry mechanism, immune response, and therapeutic implications, possible drug targets, their ongoing clinical trials, and put forward vital questions to offer new directions to the COVID-19 research.
Keywords: Clinical trials; Immune response; MERS-CoV; SARS-CoV; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare no conflict of interest.
Figures
![Image 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/fx1_lrg.gif)
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr1_lrg.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr2_lrg.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr3_lrg.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr4_lrg.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr5_lrg.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7505773/bin/gr6_lrg.gif)
Similar articles
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30. Drug Dev Res. 2021. PMID: 33216381 Review.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
-
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4. J Infect Public Health. 2020. PMID: 32778421 Free PMC article.
-
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16. FEBS J. 2020. PMID: 32446285 Free PMC article. Review.
Cited by
-
Kinetics of SARS-CoV-2 Viral Load in Hospitalized Patients.Pathogens. 2024 May 20;13(5):429. doi: 10.3390/pathogens13050429. Pathogens. 2024. PMID: 38787281 Free PMC article.
-
Identifying factors that can be used to assess a country's readiness to deploy a new vaccine or improve uptake of an underutilised vaccine: a scoping review.BMJ Open. 2024 May 7;14(5):e080370. doi: 10.1136/bmjopen-2023-080370. BMJ Open. 2024. PMID: 38719292 Free PMC article. Review.
-
The glycosaminoglycan-binding chemokine fragment CXCL9(74-103) reduces inflammation and tissue damage in mouse models of coronavirus infection.Front Immunol. 2024 Apr 15;15:1378591. doi: 10.3389/fimmu.2024.1378591. eCollection 2024. Front Immunol. 2024. PMID: 38686377 Free PMC article.
-
Prevalence and association of oral manifestations with disease severity in patients diagnosed with COVID‑19: A cross‑sectional study.Med Int (Lond). 2024 Apr 10;4(3):30. doi: 10.3892/mi.2024.154. eCollection 2024 May-Jun. Med Int (Lond). 2024. PMID: 38660127 Free PMC article.
-
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Latin America and the Caribbean: Longitudinal Trend Analysis.JMIR Public Health Surveill. 2024 May 17;10:e44398. doi: 10.2196/44398. JMIR Public Health Surveill. 2024. PMID: 38568194 Free PMC article.
References
-
- Sahin A.R. Novel coronavirus (COVID-19) outbreak: a review of the current literature. Eurasian J. Med. Investig. 2019;4:1–7. doi: 10.14744/ejmo.2020.12220. 2020. - DOI
-
- Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Chen H.-D., Chen J., Luo Y., Guo H., Jiang R.-D., Liu M.-Q., Chen Y., Shen X.-R., Wang X., Zheng X.-S., Zhao K., Chen Q.-J., Deng F., Liu L.-L., Yan B., Zhan F.-X., Wang Y.-Y., Xiao G.-F., Shi Z.-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579 doi: 10.1038/s41586-020-2012-7. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous